During their operations, they incurred losses of about 220 million dollars. The corporation was also criticized for some design elements of its clinical trials related to the need to perform critical care and resuscitation while patients were in grave clinical conditions due to the mechanisms of injury incurred and the consequent inability of patients to provide informed consent for treatment.
During their operations, they suffered financial losses of approximately 220 million dollars. The corporation faced criticism for certain design aspects of its clinical trials concerning the necessity to provide critical care and resuscitation when patients were in severe medical conditions due to injury mechanisms and the inability of patients to give informed consent for treatment.